Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

48.000
+3.3507.50%
Volume:710.03K
Turnover:33.40M
Market Cap:13.43B
PE:-22.77
High:48.000
Open:44.600
Low:44.550
Close:44.650
Loading ...

BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China

Reuters
·
25 Apr

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

THOMSON REUTERS
·
25 Apr

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

THOMSON REUTERS
·
25 Apr

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS
·
25 Apr

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS
·
25 Apr

the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

THOMSON REUTERS
·
05 Apr

Keymed Biosciences Inc. (HKG:2162) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.
·
28 Mar

Stock Track | KEYMED BIO-B Soars 5.17% Following Strong 2024 Annual Results and Pipeline Advancements

Stock Track
·
27 Mar

Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress

Stock Track
·
27 Mar

Press Release: Keymed Biosciences Announces Annual Results of 2024

Dow Jones
·
26 Mar

BRIEF-Keymed Biosciences Posts FY Revenue Of RMB428.1 Million

Reuters
·
24 Mar

KeyMed Biosciences FY Revenue RMB 36 Million

THOMSON REUTERS
·
24 Mar

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS
·
08 Feb

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS
·
08 Feb

Keymed Biosciences Get China Nod for Supplementary NDA of Rhinitis Drug

MT Newswires Live
·
07 Feb

KeyMed Biosciences - Nmpa Approved Snda of Stapokibart for Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS
·
07 Feb

Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug

MT Newswires Live
·
21 Jan

InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug

MT Newswires Live
·
21 Jan

InnoCare and KeyMed Jointly Announce the License Agreement With Prolium for Cd20xcd3 Bispecific Antibody Icp-B02

THOMSON REUTERS
·
20 Jan

BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355

Reuters
·
20 Jan